Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Microsystem Reduces Cost of Developing Ion Channel Drugs

By BiotechDaily International staff writers
Posted on 11 Dec 2013
Print article
Image: Schematic diagram of an ion channel. 1 - channel domains (typically four per channel), 2 - outer vestibule, 3 - selectivity filter, 4 - diameter of selectivity filter, 5 - phosphorylation site, 6 - cell membrane (Photo courtesy of Wikimedia Commons).
Image: Schematic diagram of an ion channel. 1 - channel domains (typically four per channel), 2 - outer vestibule, 3 - selectivity filter, 4 - diameter of selectivity filter, 5 - phosphorylation site, 6 - cell membrane (Photo courtesy of Wikimedia Commons).
The use of a microsystem that generates ion channels in a cell-free medium is expected to boost development of drugs that target these channels in the treatment of diseases such as cystic fibrosis, myasthenia gravis, and epilepsy.

The effect of drugs on ion channels is currently studied by electrophysiology, which measures an electric current across ion channel proteins. This, however, is a slow and expensive process that is carried out using ion channels in living cell membranes.

In a paper published in the October 18, 2013, online edition of the journal Analyst, investigators at the University of Southampton (United Kingdom) in collaboration with colleagues at the University of Quebec (Montreal, Canada) described the development of a cell-free expression mixture that allows ion channels to be inserted into stable artificial "cell membranes."

Results of the study showed that single-channel current measurements of the potassium channels KcsA and hERGS5–S6 could be obtained by direct insertion in interdroplet lipid bilayers from microliters of a cell-free expression medium.

"By putting the ion channel into an artificial membrane, we only have one type of channel, no living cells, and a relatively inexpensive method for testing for several of these types of channels at once," said senior author Dr. Maurits de Planque, lecturer in electronics and computer science at the University of Southampton. "Researchers have experimented with cell-free mixtures before, but they found that this method was not economical due to the amount of expensive biochemicals required. Our proposal to develop a new platform, which uses a couple of microliters instead of milliliters, will be a very cost-effective way of doing this, particularly when the produced channel is directly inserted in a membrane for drug testing."

Related Links:

University of Southampton
University of Quebec



Print article

Channels

Genomics/Proteomics

view channel
Image: A confocal microscopy image of human fibroblasts derived from embryonic stem cells. The nuclei appear in blue, while smaller and more numerous mitochondria appear in red (Photo courtesy of Dr. Shoukhrat Mitalipov, Oregon Health & Science University).

Stem Cells Derived from Older Individuals May Carry Unsafe Mitochondrial DNA Mutations

Induced pluripotent stem cells (iPSCs) derived from the skin fibroblasts of older individuals have a likelihood of harboring mitochondrial DNA mutations, which may render them unfit for clinical applications.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.